sponsorship of Medscape, LLC and JNCCN - The Journal of the National Comprehensive Cancer Network . Medscape, LLC is accredited by the ACCME to provide continuing medical education for physicians. Medscape, LLC designates this Journal-based CME activity for
Alex J. Mitchell
distress, which had previously received little attention compared with depression. 1 Distress is a very common complication of cancer at any stage and often occurs when multiple needs are unmet. 2 , 3 The presence of distress is also linked with reduced
Benjamin J. Miriovsky and Thomas L. Ortel
is the basis for treatment with direct thrombin inhibitors. 7 The heparin-PF4 antibodies are detectable in the laboratory using immunologic or functional assays, and are often used to support the clinical suspicion of HIT. Patients with cancer
Bhumsuk Keam, Jeong-Hoon Lee, Seock-Ah Im and Jung-Hwan Yoon
Korea, which is regarded as an endemic area of HBV infection, a nationwide survey revealed an HBsAg prevalence of 5.1% in men and 4.1% in women. 4 Reactivation of HBV has been well documented in infected patients receiving chemotherapy for cancer
Robert Swarm, Amy Pickar Abernethy, Doralina L. Anghelescu, Costantino Benedetti, Craig D. Blinderman, Barry Boston, Charles Cleeland, Nessa Coyle, Oscar A. deLeon-Casasola, June G. Eilers, Betty Ferrell, Nora A. Janjan, Sloan Beth Karver, Michael H. Levy, Maureen Lynch, Natalie Moryl, Barbara A. Murphy, Suzanne A. Nesbit, Linda Oakes, Eugenie A. Obbens, Judith A. Paice, Michael W. Rabow, Karen L. Syrjala, Susan Urba and Sharon M. Weinstein
Overview Pain, defined as “a sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage,” 1 is one of the most common symptoms associated with cancer. Cancer pain or cancer
Muhammed Aasim Yusuf, Vinay Kumar Kapoor, Refaat Refaat Kamel, Ather Kazmi, Najam Uddin, Nehal Masood and Abdulmajeed Al-Abdulkareem
T he 2009 version of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) on Hepatobiliary Cancers (to view the most recent version of these guidelines, visit the NCCN Web site at www.NCCN.org ) addresses 4 main tumor groups
Al B. Benson III, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Michael A. Choti, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Marwan G. Fakih, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Lucille A. Leong, Edward Lin, Michael G. Martin, Kilian Salerno May, Mary F. Mulcahy, Kate Murphy, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, William Small Jr, Constantinos T. Sofocleous, Alan P. Venook, Christopher G. Willett, Deborah A. Freedman-Cass and Kristina M. Gregory
appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview
Randall W. Burt, Jamie A. Cannon, Donald S. David, Dayna S. Early, James M. Ford, Francis M. Giardiello, Amy L. Halverson, Stanley R. Hamilton, Heather Hampel, Mohammad K. Ismail, Kory Jasperson, Jason B. Klapman, Audrey J. Lazenby, Patrick M. Lynch, Robert J. Mayer, Reid M. Ness, Dawn Provenzale, M. Sambasiva Rao, Moshe Shike, Gideon Steinbach, Jonathan P. Terdiman, David Weinberg, Mary Dwyer and Deborah Freedman-Cass
appropriate. All recommendations are category 2A unless otherwise noted. Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. Overview
Kaylene Ready and Banu Arun
B reast cancer is the most common cancer among women in the United States with a lifetime risk of 1 in 8 (12%). 1 Multiple risk factors for breast cancer have been identified and include gender, age, race, benign breast disease (atypical ductal
Carmen P. Escalante, Ellen Manzullo and Rosalie Valdres
The authors receive grant funding from Ortho Biotech Oncology. References 1 Mock V Atkinson A Barsevick A NCCN cancer-related fatigue clinical practice guidelines in oncology . Oncology 2000 ; 14 : 151 – 161 . 2
